The HPV vaccine is pushing cervical cancer deaths toward zero

A generation ago, cervical cancer often turned on timing. The disease could be caught early and treated, but only if screening happened at the right age, and only if the virus behind nearly every case had not already been acquired years earlier. Women who came just before school-age HPV vaccination became routine still live with that timing in a brutally personal way. Girls who arrived just after may be entering a different calendar altogether.

Peter Sasieni and colleagues tried to measure that shift in a 2026 Lancet Regional Health study, using a target-trial emulation design to estimate how HPV vaccination changed the risk of invasive cervical cancer and related precancerous lesions. Read with England’s recent mortality figures, the study suggests women vaccinated in early adolescence now face close to zero risk of dying from cervical cancer before age 30.

Here is the careful version of the headline. Cervical cancer has not vanished. Instead, when vaccination happens early enough, and when later screening still does its part, the disease appears to lose its grip on the youngest adult cohorts first. That is a more consequential story than the older HPV headlines about abnormal cells alone. It also puts the celebration beside harder questions about the study design, the age window, and England’s path to elimination.

Why this headline lands differently

Until recently, England’s strongest HPV-vaccine evidence sat one step upstream from mortality. Researchers showed fewer high-grade cervical lesions, then fewer invasive cancers, among girls vaccinated at younger ages. A 2024 BMJ analysis of England’s vaccination programme helped establish that shift, finding substantial reductions in cervical cancer incidence and grade 3 cervical intraepithelial neoplasia in cohorts offered the vaccine in adolescence. Important, yes, but still one stage short of the endpoint most people hear most clearly: death.

During the last decade, the public-health arc has moved from precancer markers, to invasive cancer, to the harder question of whether fewer young women actually die. Longer follow-up is needed at each step. Optimism alone carries less weight as the endpoint gets more severe.

Mortality changes the tone. In the English data discussed alongside the new paper, there were zero cervical-cancer deaths among women aged 20 to 24 between 2020 and 2024, and researchers estimate that roughly 200 lives have already been saved since the programme began. Cervical cancer is still diagnosed in about 3,300 women a year in England, but the youngest women vaccinated early appear to be entering adulthood with a very different risk profile from the cohorts just ahead of them.

Sasieni described that shift in BBC News’ reporting as evidence that a preventive intervention has started to alter a once-familiar cancer curve, not as a victory slogan.

“It’s incredible to think that a single jab can almost eliminate a particular type of cancer.”
Peter Sasieni, BBC News

One easy mistake would be to read that quote too broadly. The evidence does not show that one dose, by itself, abolishes all future cervical-cancer risk for every vaccinated person. What it shows is that an early population vaccination programme is now strong enough to change the hardest outcome in the youngest age band where the first vaccinated cohorts can be measured.

What the study actually measured

Target-trial emulation is a way of rebuilding, from observational data, the comparison a randomised trial would ideally have made. In this case, the Lancet Regional Health paper drew on national vaccination and cancer data to compare cohorts by age at vaccination, then estimated how those timing differences translated into later invasive cancer risk.

For HPV prevention, timing is not a side issue. A school-age programme reaches people before most sexual exposure, which is why the benefit tends to be steepest in those vaccinated youngest. The English story now emerging is less about a magic threshold than a sequence: vaccinate early, keep coverage high, keep screening available, then wait long enough for those cohorts to age into the years when early cancers and, eventually, early deaths would otherwise appear.

One caveat follows directly from that design. “Before 30” is the age window the data can currently illuminate most clearly. Cervical cancer remains more common later in life, which means the longest and most policy-important question is still ahead: whether the cohorts who now look protected in their twenties keep the same advantage into their thirties and beyond. A near-zero mortality signal before 30 is powerful evidence, not the final chapter.

Even with that limit, the paper is a real upgrade from the evidence base that existed a few years ago. Earlier programme evaluations showed fewer precancers and fewer cancers. This analysis, together with England’s recent death data, suggests those reductions are now large enough to reach mortality itself. Prevention science starts to sound different at that point. Less promise, more proof.

The women just outside the vaccine cohort are part of the story too

Population curves can hide the sharp human edge of a transition period. Every breakthrough has a seam: people born a little too early, living in the wrong postcode, missing the offer, or never getting the follow-up test. In the UK’s reporting on the new findings, cervical-cancer survivor Alexandra Legg sits at that seam, a reminder that the cohorts now benefiting most were not always guaranteed the same protection.

Legg describes the shock of diagnosis in the BBC account in a way that cuts through incidence curves and vaccination tables.

“I remember hearing the words and I just couldn’t really breathe very well.”
Alexandra Legg, BBC News

Her place in the story matters because the vaccine does not erase the obligation to look for disease in people who were never fully protected, or who may still develop cancer despite protection. Cervical screening remains part of the same prevention system, not a consolation prize after the real intervention has happened. Vaccine headlines can make public health sound like a single heroic act. In practice it is a layered routine.

Deaths linger in the discussion for another reason. A drop in abnormal cells is encouraging. A drop in invasive cancer is stronger. A period with no deaths in women aged 20 to 24 changes the emotional texture of the evidence, because it brings the benefit into the language families and patients actually use. Not risk markers. Not lesions. Lives not lost.

No group gets an exemption from that layered system. Women in partially vaccinated or unvaccinated cohorts still need screening. Highly vaccinated cohorts still need a service that can detect the rare cases that do occur. The vaccine shifts the odds. Care still has to show up.

Elimination is a public-health job, not a victory lap

Policy is the complication now. England’s younger cohorts are benefiting from a prevention strategy that works, but current vaccination coverage still sits below the World Health Organization’s 90 percent target by age 15. The figure cited for England in 2024-25 is 76 percent. High enough to matter, clearly. Not high enough to call the job complete.

A separate 2026 BMJ Public Health modelling study puts that caution into timeline form. With current screening and vaccination levels, the model estimated that England could eliminate cervical cancer as a public-health problem around 2050. That would be a huge achievement compared with the pre-vaccine era, but it is later than it might be if uptake improved, follow-up after abnormal screening were more consistent, and gaps in access narrowed.

In the Guardian’s coverage, Temmink made the public-facing version of that point: the promise of the vaccine depends on actually receiving it.

“cervical cancer and some other cancers shouldn’t be a risk for you.”
Caroline Temmink, The Guardian

Should not is the important phrase. Not will not, under every circumstance, forever. Should not, if the programme reaches people in time, if they accept it, if screening remains part of routine care, and if health systems treat follow-up as a priority rather than an administrative detail.

Seen that way, the study matters beyond its headline. It offers proof that HPV vaccination is not simply reducing surrogate markers or nudging lifetime risk curves in the right direction. In the first cohorts old enough to test the question, it appears to be changing who dies young from cervical cancer. For a field that has spent years translating virology, behaviour, screening intervals, and cancer registries into something legible to the public, the result is unusually plain.

Flattening the finding into a slogan about a cancer being almost eliminated would miss the operating lesson. England is seeing what happens when a vaccine arrives early enough, at high enough scale, and is backed by a screening system sturdy enough to catch what vaccination does not. The youngest cohorts are showing the payoff first. Whether the elimination story keeps moving depends on a less glamorous task: keeping the routine parts of prevention as strong as the breakthrough ones.

References

1. Sasieni P, et al. The effectiveness of HPV vaccination against invasive cervical cancer and related precancerous lesions: a multinational target trial emulation study. The Lancet Regional Health. 2026. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00009-9/fulltext
2. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia in England. BMJ. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11094700/
3. Modelling the time to cervical cancer elimination in England: strategies for achieving elimination by 2040. BMJ Public Health. 2026. https://bmjpublichealth.bmj.com/content/4/1/e004290